Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 172,084 shares of Lexaria Bioscience Corp. common stock as of September 30, 2026.

Key Highlights

  • Reporting persons: Armistice Capital, LLC (Delaware) and Steven Boyd (United States) filed jointly as the "Reporting Persons."
  • Shares beneficially owned: 172,084 shares of Lexaria Bioscience Corp. common stock, par value $0.001 per share (CUSIP 52886N604).
  • Percent of class: 8.17% of the outstanding class, according to the filing.
  • Voting and dispositive power: Both Armistice Capital and Steven Boyd report 0 sole voting power and 0 sole dispositive power, with 172,084 shares each under shared voting and shared dispositive power.
  • Direct holder: The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, which is an investment advisory client of Armistice Capital.
  • Event date: The date of the event requiring this filing is September 30, 2026.

Armistice Capital and Steven Boyd Disclose Shared Control Over Lexaria Bioscience Position

According to the Schedule 13G filed on November 16, 2026, Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., described in the filing as "the direct holder of the Shares." The filing states that "pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund." Steven Boyd, as the managing member of Armistice Capital, is similarly reported to beneficially own the securities held by the Master Fund.

The filing further notes that "The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital." Regarding receipt of proceeds, the filing states that the Master Fund "has the right to receive dividends from, or the proceeds from the sale of, the reported securities."

Both reporting persons certified, as required by Schedule 13G, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Lexaria Bioscience Corp. is listed on NASDAQ:LEXX and is headquartered at 100 - 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7, according to the filing.

What Was Disclosed

Armistice Capital, LLC and Steven Boyd jointly reported beneficial ownership of 172,084 shares of Lexaria Bioscience Corp. common stock, representing 8.17% of the class, with all voting and dispositive power held on a shared basis as of September 30, 2026.